Victory Capital Management
OTLK icon

Victory Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Victory Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-888
Closed -$7K – 2549
2023
Q4 		$7K Buy
888
+187
+27% +$1.58K ﹤0.01% 2534
2023
Q3 		$3.1K Buy
701
+27
+4% +$597 ﹤0.01% 2511
2023
Q2 		$23.5K Sell
674
-16
-2% -$436 ﹤0.01% 2437
2023
Q1 		$15K Sell
690
-67
-9% -$1.5K ﹤0.01% 2528
2022
Q4 		$16.4K Hold
757
– – ﹤0.01% 2521
2022
Q3 		$18K Sell
757
-195
-20% -$4.53K ﹤0.01% 2636
2022
Q2 		$19K Buy
952
+64
+7% +$1.84K ﹤0.01% 2623
2022
Q1 		$28K Buy
888
+3
+0.3% +$94 ﹤0.01% 2628
2021
Q4 		$24K Buy
885
+195
+28% +$6.96K ﹤0.01% 2686
2021
Q3 		$30K Sell
690
-35
-5% -$1.69K ﹤0.01% 2713
2021
Q2 		$36K Sell
725
-22
-3% -$1.02K ﹤0.01% 2684
2021
Q1 		$34K Buy
+747
New +$28.6K ﹤0.01% 2694
2020
Q2 		– Sell
-536
Closed -$6K – 3040
2020
Q1 		$6K Buy
+536
New +$8.89K ﹤0.01% 3437
2019
Q4 		– Sell
-106
Closed -$3K – 3070
2019
Q3 		$3K Buy
+106
New +$4.09K ﹤0.01% 3568

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Victory Capital Management's OTLK Position: Q1 2024 in Review

Victory Capital Management sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 888 shares — an estimated $7K sold.

Victory Capital Management first reported a position in OTLK in Q3 2019 and held it in 14 quarters. The position peaked at $36K in Q2 2021. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Victory Capital Management reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Victory Capital Management sold 888 Outlook Therapeutics shares in Q1 2024, an estimated $7K.
  • Victory Capital Management first reported a position in Outlook Therapeutics in Q3 2019 and held it in 14 quarters.
  • Victory Capital Management's Outlook Therapeutics position peaked at $36K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Victory Capital Management's 13F filing for Q1 2024, filed 3 May 2024.